Neurotech startup Synchron acquired a minority equity stake in manufacturer Acquandas to ramp up production. Acquandas has the unique ability to layer metals used in Synchron's implantable brain-computer interface. The deal gives Synchron exclusive access to this tech, and its CEO and CTO joined Acquandas' board. Synchron is prepping for commercialization and estimates millions of people living with paralysis could benefit from its technology. Synchron aims to expand its manufacturing and is set to launch a patient registry in mid-February.
